{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:56:12Z","timestamp":1772027772498,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of\n                  Health","doi-asserted-by":"publisher","award":["AG18440"],"award-info":[{"award-number":["AG18440"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tauopathies are a group of neurodegenerative disorders with\n                  accumulation of three-repeat (3R) or four-repeat (4R) Tau. While 3R tau is found\n                  in Pick\u2019s disease and Alzheimer\u2019s disease (AD), 4R tau is more abundant in\n                  corticobasal degeneration, progressive supranuclear palsy, and AD. We have\n                  previously shown that Cerebrolysin\u2122 (CBL), a neuropeptide mixture with\n                  neurotrophic effects, ameliorates the pathology in amyloid precursor protein\n                  transgenic (tg) mouse model of AD and 4R tau, however it is unclear if CBL\n                  ameliorates the deficits and neuropathology in the mouse model of Pick\u2019s disease\n                  over expressing 3R tau.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mice expressing 3R tau (L266V and G272V mutations) under the mThy-1\n                  promoter were treated with CBL in two separate groups, the first was 3\u00a0months old\n                  (treated for 3\u00a0months, IP) and the second was 6\u00a0months old (treated for 3\u00a0months,\n                  IP) at the start of the treatment. We found that although the levels of total 3R\n                  tau were unchanged, CBL reduced the levels of hyper-phosphorylated tau in both\n                  groups of mice. This was accompanied by reduced neurodegenerative pathology in the\n                  neocortex and hippocampus in both groups and by improvements in the behavioral\n                  deficits in the nest-building test and water maze in the 3\u20136\u00a0month group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Taken together these results support the notion that CBL may be\n                  beneficial in other taupathy models by reducing the levels of aberrantly\n                  phosphorylated tau.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12868-015-0218-7","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T13:06:15Z","timestamp":1448543175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["RETRACTED ARTICLE: Neuroprotective\n              effects of Cerebrolysin in triple repeat Tau transgenic model of Pick\u2019s disease and\n              fronto-temporal tauopathies"],"prefix":"10.1186","volume":"16","author":[{"given":"Edward","family":"Rockenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiren","family":"Ubhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazmin","family":"Florio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Adame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemma","family":"Brandstaetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"issue":"3","key":"218_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/JAD-2005-8301","volume":"8","author":"C del","year":"2005","unstructured":"del C, Alonso A, Iqbal K. Tau-induced neurodegeneration: a clue to\n                  its mechanism. J Alzheimer\u2019s Dis. 2005;8(3):223\u20136.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"43","key":"218_CR2","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1021\/bi00158a027","volume":"31","author":"A Andreadis","year":"1992","unstructured":"Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the\n                  human tau gene. Biochemistry. 1992;31(43):10626\u201333.","journal-title":"Biochemistry"},{"issue":"3","key":"218_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of\n                  frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci.\n                  2011;45(3):384\u20139.","journal-title":"J Mol Neurosci"},{"key":"218_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","volume":"24","author":"VM Lee","year":"2001","unstructured":"Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies.\n                  Annu Rev Neurosci. 2001;24:1121\u201359.","journal-title":"Annu Rev Neurosci"},{"issue":"8","key":"218_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.neurobiolaging.2003.04.007","volume":"24","author":"EM Mandelkow","year":"2003","unstructured":"Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of\n                  axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol\n                  Aging. 2003;24(8):1079\u201385.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"218_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D,\n                  Waters C, Jimison P, Shepherd E, Sevush S, et al. Relative frequencies of\n                  Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and\n                  hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc\n                  Disord. 2002;16(4):203\u201312.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Pt 11","key":"218_CR7","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/brain\/awh591","volume":"128","author":"IF Bronner","year":"2005","unstructured":"Bronner IF, ter Meulen BC, Azmani A, Severijnen LA, Willemsen R,\n                  Kamphorst W, Ravid R, Heutink P, van Swieten JC. Hereditary Pick\u2019s disease with\n                  the G272V tau mutation shows predominant three-repeat tau pathology. Brain: J\n                  Neurol. 2005;128(Pt 11):2645\u201353.","journal-title":"Brain: J Neurol"},{"issue":"4","key":"218_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00401-003-0734-x","volume":"106","author":"M Hogg","year":"2003","unstructured":"Hogg M, Grujic ZM, Baker M, Demirci S, Guillozet AL, Sweet AP,\n                  Herzog LL, Weintraub S, Mesulam MM, LaPointe NE, et al. The L266V tau mutation is\n                  associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta\n                  Neuropathol. 2003;106(4):323\u201336.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"218_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/00005072-199912000-00002","volume":"58","author":"JR Murrell","year":"1999","unstructured":"Murrell JR, Spillantini MG, Zolo P, Guazzelli M, Smith MJ, Hasegawa\n                  M, Redi F, Crowther RA, Pietrini P, Ghetti B, et al. Tau gene mutation G389R\n                  causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J\n                  Neuropathol Exp Neurol. 1999;58(12):1207\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5\u20136","key":"218_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0361-9230(99)00139-2","volume":"50","author":"B Ghetti","year":"1999","unstructured":"Ghetti B, Murrell J, Spillantini MG. Mutations in the Tau gene\n                  cause frontotemporal dementia. Brain Res Bull.\n                  1999;50(5\u20136):471\u20132.","journal-title":"Brain Res Bull"},{"issue":"7","key":"218_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s007020070061","volume":"107","author":"E Ruther","year":"2000","unstructured":"Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch\n                  M. Sustained improvements in patients with dementia of Alzheimer\u2019s type (DAT)\n                  6\u00a0months after termination of Cerebrolysin therapy. J Neural Transm.\n                  2000;107(7):815\u201329.","journal-title":"J Neural Transm"},{"issue":"2","key":"218_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00702-004-0181-4","volume":"112","author":"E Rockenstein","year":"2005","unstructured":"Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M,\n                  Moessler H, Masliah E. Amelioration of the cerebrovascular amyloidosis in a\n                  transgenic model of Alzheimer\u2019s disease with the neurotrophic compound\n                  Cerebrolysin. J Neural Transm. 2005;112(2):269\u201382.","journal-title":"J Neural Transm"},{"issue":"11","key":"218_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00702-003-0025-7","volume":"110","author":"E Rockenstein","year":"2003","unstructured":"Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E.\n                  The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer\u2019s\n                  disease are associated with improved behavioral performance. J Neural Transm.\n                  2003;110(11):1313\u201327.","journal-title":"J Neural Transm"},{"key":"218_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-3-7091-6139-5_31","volume":"62","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler\n                  H, Masliah E. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic\n                  model of Alzheimer\u2019s disease. J Neural Transm Suppl.\n                  2002;62:327\u201336.","journal-title":"J Neural Transm Suppl"},{"issue":"3","key":"218_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00401-006-0166-5","volume":"113","author":"E Rockenstein","year":"2007","unstructured":"Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E.\n                  Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer\u2019s\n                  disease. Acta Neuropathol. 2007;113(3):265\u201375.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"218_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-009-0505-4","volume":"117","author":"K Ubhi","year":"2009","unstructured":"Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C,\n                  Trejo M, Crews L, Paulino A, Moessler H, et al. Neurofibrillary and\n                  neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU:\n                  neuroprotective effects of Cerebrolysin. Acta Neuropathol.\n                  2009;117(6):699\u2013712.","journal-title":"Acta Neuropathol"},{"key":"218_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2202-15-90","volume":"15","author":"E Rockenstein","year":"2014","unstructured":"Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Adame A, Novak\n                  P, Jech M, Doppler E, Moessler H, et al. Cerebrolysin efficacy in a transgenic\n                  model of tauopathy: role in regulation of mitochondrial structure. BMC Neurosci.\n                  2014;15:90.","journal-title":"BMC Neurosci"},{"issue":"2","key":"218_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jnr.23142","volume":"91","author":"K Ubhi","year":"2013","unstructured":"Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick\n                  C, Adame A, Fahnestock M, Doppler E, Novak P, et al. Cerebrolysin modulates\n                  pronerve growth factor\/nerve growth factor ratio and ameliorates the cholinergic\n                  deficit in a transgenic model of Alzheimer\u2019s disease. J Neurosci Res.\n                  2013;91(2):167\u201377.","journal-title":"J Neurosci Res"},{"issue":"3","key":"218_CR19","doi-asserted-by":"publisher","first-page":"e0121570","DOI":"10.1371\/journal.pone.0121570","volume":"10","author":"E Rockenstein","year":"2015","unstructured":"Rockenstein E, Overk CR, Ubhi K, Mante M, Patrick C, Adame A,\n                  Bisquert A, Trejo-Morales M, Spencer B, Masliah E. A novel triple repeat mutant\n                  Tau Transgenic Model that mimics aspects of Pick\u2019s disease and fronto-temporal\n                  tauopathies. PLoS One. 2015;10(3):e0121570.","journal-title":"PLoS One"},{"issue":"4","key":"218_CR20","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A,\n                  Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces\n                  behavioral and neuropathological deficits in an alpha-synuclein transgenic model\n                  of Lewy body disease. PLoS One. 2011;6(4):e19338.","journal-title":"PLoS One"},{"issue":"4","key":"218_CR21","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.ajpath.2010.12.033","volume":"178","author":"C Patrick","year":"2011","unstructured":"Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL,\n                  Everall IP, Masliah E. Increased CDK5 expression in HIV encephalitis contributes\n                  to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am\n                  J Pathol. 2011;178(4):1646\u201361.","journal-title":"Am J Pathol"},{"issue":"5","key":"218_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00005072-199705000-00006","volume":"56","author":"W Samuel","year":"1997","unstructured":"Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy\n                  bodies versus pure Alzheimer disease: differences in cognition, neuropathology,\n                  cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol.\n                  1997;56(5):499\u2013508.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"218_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.nbd.2009.06.004","volume":"35","author":"CR Overk","year":"2009","unstructured":"Overk CR, Kelley CM, Mufson EJ. Brainstem Alzheimer\u2019s-like\n                  pathology in the triple transgenic mouse model of Alzheimer\u2019s disease. Neurobiol\n                  Dis. 2009;35(3):415\u201325.","journal-title":"Neurobiol Dis"},{"issue":"Suppl A","key":"218_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1358\/dot.2012.48(Suppl.A).1739716","volume":"48","author":"E Masliah","year":"2012","unstructured":"Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic\n                  treatment with Cerebrolysin: brain protection and repair to counteract pathologies\n                  of acute and chronic neurological disorders. Drugs Today. 2012;48(Suppl\n                  A):3\u201324.","journal-title":"Drugs Today"},{"key":"218_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnagi.2014.00232","volume":"6","author":"JF Castro-Alvarez","year":"2014","unstructured":"Castro-Alvarez JF, Uribe-Arias SA, Mejia-Raigosa D, Cardona-Gomez\n                  GP. Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems\n                  biology approach. Front Aging Neurosci. 2014;6:232.","journal-title":"Front Aging Neurosci"},{"key":"218_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","volume":"7","author":"T Kimura","year":"2014","unstructured":"Kimura T, Ishiguro K, Hisanaga S. Physiological and pathological\n                  phosphorylation of tau by Cdk5. Front Mol Neurosci. 2014;7:65.","journal-title":"Front Mol Neurosci"},{"issue":"Suppl 1","key":"218_CR27","first-page":"S141","volume":"33","author":"F Hernandez","year":"2013","unstructured":"Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence\n                  points in Alzheimer\u2019s disease. J Alzheimers Dis. 2013;33(Suppl\n                  1):S141\u20134.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 1","key":"218_CR28","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.3233\/JAD-132054","volume":"40","author":"DP Hanger","year":"2014","unstructured":"Hanger DP, Lau DH, Phillips EC, Bondulich MK, Guo T, Woodward BW,\n                  Pooler AM, Noble W. Intracellular and extracellular roles for tau in\n                  neurodegenerative disease. J Alzheimers Dis. 2014;40(Suppl\n                  1):S37\u201345.","journal-title":"J Alzheimers Dis"},{"key":"218_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-385883-2.00004-7","volume":"107","author":"G Lee","year":"2012","unstructured":"Lee G, Leugers CJ. Tau and tauopathies. Prog Mol Biol Transl Sci.\n                  2012;107:263\u201393.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"7","key":"218_CR30","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jnr.20818","volume":"83","author":"E Rockenstein","year":"2006","unstructured":"Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB,\n                  Crews L, Moessler H, Masliah E. Cerebrolysin decreases amyloid-beta production by\n                  regulating amyloid protein precursor maturation in a transgenic model of\n                  Alzheimer\u2019s disease. J Neurosci Res. 2006;83(7):1252\u201361.","journal-title":"J Neurosci Res"},{"key":"218_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijdevneu.2014.07.005","volume":"38","author":"K Hartwig","year":"2014","unstructured":"Hartwig K, Fackler V, Jaksch-Bogensperger H, Winter S, Furtner T,\n                  Couillard-Despres S, Meier D, Moessler H, Aigner L. Cerebrolysin protects PC12\n                  cells from CoCl2-induced hypoxia employing GSK3\u03b2 signaling.\n                  Int J Dev Neurosci. 2014;38:52\u20138.","journal-title":"Int J Dev Neurosci"},{"issue":"6","key":"218_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00401-002-0587-8","volume":"104","author":"I Ferrer","year":"2002","unstructured":"Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is\n                  associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer\u2019s\n                  disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal\n                  degeneration. Acta Neuropathol. 2002;104(6):583\u201391.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"218_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00401-002-0600-2","volume":"104","author":"I Ferrer","year":"2002","unstructured":"Ferrer I, Barrachina M, Puig B. Anti-tau phospho-specific Ser262\n                  antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in\n                  tauopathies including Pick bodies and argyrophilic grains. Acta Neuropathol.\n                  2002;104(6):658\u201364.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"218_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","volume":"114","author":"NJ Cairns","year":"2007","unstructured":"Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ,\n                  White CL 3rd, Schneider JA, Grinberg LT, Halliday G, et al. Neuropathologic\n                  diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus\n                  of the consortium for frontotemporal lobar degeneration. Acta Neuropathol.\n                  2007;114(1):5\u201322.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"218_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2990.2012.01272.x","volume":"39","author":"GG Kovacs","year":"2013","unstructured":"Kovacs GG, Rozemuller AJ, van Swieten JC, Gelpi E, Majtenyi K,\n                  Al-Sarraj S, Troakes C, Bodi I, King A, Hortobagyi T, et al. Neuropathology of the\n                  hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe\n                  Consortium. Neuropathol Appl Neurobiol. 2013;39(2):166\u201378.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"218_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2990.2012.01272.x","volume":"39","author":"GG Kovacs","year":"2013","unstructured":"Kovacs GG, Rozemuller AJ, van Swieten JC, Gelpi E, Majtenyi K,\n                  Al-Sarraj S, Troakes C, Bodi I, King A, Hortobagyi T, et al. Neuropathology of the\n                  hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe\n                  Consortium. Neuropathol Appl Neurobiol. 2013;39(2):166\u201378.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"218_CR37","doi-asserted-by":"publisher","first-page":"a006437","DOI":"10.1101\/cshperspect.a006437","volume":"1","author":"VM Lee","year":"2011","unstructured":"Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing\n                  therapeutic approaches to tau, selected kinases, and related neuronal protein\n                  targets. Cold Spring Harb Perspect Med. 2011;1(1):a006437.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"218_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.expneurol.2010.10.007","volume":"230","author":"K Ubhi","year":"2011","unstructured":"Ubhi K, Masliah E. Recent advances in the development of\n                  immunotherapies for tauopathies. Exp Neurol. 2011;230(2):157\u201361.","journal-title":"Exp Neurol"},{"issue":"3","key":"218_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","volume":"138","author":"E Valera","year":"2013","unstructured":"Valera E, Masliah E. Immunotherapy for neurodegenerative diseases:\n                  focus on alpha-synucleinopathies. Pharmacol Ther.\n                  2013;138(3):311\u201322.","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"218_CR40","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3233\/JAD-132435","volume":"40","author":"EE Congdon","year":"2014","unstructured":"Congdon EE, Krishnaswamy S, Sigurdsson EM. Harnessing the immune\n                  system for treatment and detection of tau pathology. J Alzheimers Dis.\n                  2014;40(Suppl 1):S113\u201321.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"218_CR41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12031-011-9576-5","volume":"45","author":"J Gu","year":"2011","unstructured":"Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J Mol Neurosci.\n                  2011;45(3):690\u20135.","journal-title":"J Mol Neurosci"}],"updated-by":[{"DOI":"10.1186\/s12868-025-00942-y","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"record-id":"62628"},{"DOI":"10.1186\/s12868-025-00942-y","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000}}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-015-0218-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0218-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:45:28Z","timestamp":1741607128000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/s12868-015-0218-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1186\/s12868-015-0218-7","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]},"assertion":[{"value":"3 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more\n                    detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12868-025-00942-y","URL":"https:\/\/doi.org\/10.1186\/s12868-025-00942-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"85"}}